EPSILOGEN
1.5.2024 08:01:28 CEST | Business Wire | Press release
Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces the appointments of Ashley Nagle as Chief Business Officer (CBO) and Peter Finan, currently a Non-Executive Director, as Non-Executive Chairman. The changes are made with immediate effect as part of a broader company expansion.
Ashley brings over 25 years of experience leading business and strategy development, licensing and deal-making within the biopharmaceutical industry. Most recently, Ashley served as VP of Business Development at RemedyBio, a discovery and development precision immunotherapy company. During his career Mr Nagle has worked with both small and large organisations, including Lonza Biologics, Almac Sciences, Fulcrum Pharma, OncoSynergy, NexGenix and SeaGull Therapeutics, where he was Chief Executive Officer. Ashley holds a BSc in Chemistry from University College Cork, an MSc in Analytical Chemistry and Environmental Sciences from the University of Aberdeen and an MBA from the University of Lincoln.
Ashley’s appointment comes amidst a broader company expansion that will enable Epsilogen to unlock the potential of both IgE antibodies and their engineered derivatives as an entirely new treatment modality for patients with cancer. Since the start of 2023, the company has expanded its management team with the appointments of Nick Robbins-Cherry as CFO, Andrew Calam as VP of Clinical Operations and Elizabeth Hardaker as VP of Biology. Over this period, Epsilogen has also built a world class scientific team based in state-of-the-art laboratories in West London. This investment has added internal core competencies in antibody discovery, evaluation, engineering, production and pharmacological assessment, all complementing its existing expertise within the IgE field.
Pete replaces Dave Chiswell as Non-Executive Chairman, who is stepping down for personal reasons after five years in the role. Pete has more than 30 years’ experience in drug discovery within the biopharmaceutical industry and is a Partner at Epidarex Capital. During his career Pete has also served as Global Head of the Respiratory Disease Area and Site Head for the Novartis Institute of BioMedical Research in the UK and as Executive Director of the Novartis Developmental and Molecular Pathways Platform based in Cambridge, Massachusetts. Pete holds a BSc and Ph.D. in Biochemistry and Molecular Biology from the University of Leeds.
Dr Tim Wilson, Chief Executive Officer of Epsilogen, commented: “I am delighted to welcome Ashley to the Epsilogen team. He has an excellent track record in business development within the biopharmaceutical industry and we expect his experience and insights to have an immediate impact. Epsilogen has made substantial progress over the last 12 months on all fronts and Ashley will spearhead our partnering discussions going forward.
I would like to thank Dave for all his passion and hard work in guiding Epsilogen as Non-Executive Chair over the last five years. His wealth of experience has been invaluable to the progress we have made so far, and we wish him the very best for the future. At the same time, I would like to welcome Pete on stepping up into the role. Pete has been a key member of the Epsilogen team for many years and was pivotal in its formation.”
Ashley Nagle, Chief Business Officer of Epsilogen, added: “I am excited to be joining a company with such a potentially disruptive therapeutic approach and one that has already generated encouraging early clinical and preclinical data. I look forward to working closely with Tim and the rest of the team to fully unlock the value of this class of antibodies and leverage my strategy and business development expertise to drive Epsilogen forward.”
Dr Dave Chiswell, outgoing Non-Executive Chairman of Epsilogen, said: “I have thoroughly enjoyed working with all of the Epsilogen team and am proud of what we have achieved together. The company is in excellent hands and is in a good position to execute the next phase of its development, as it pursues its ambition to revolutionise cancer treatment with IgE antibodies.”
About Epsilogen Ltd
Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE’s natural function is to provide immunological defence against certain parasites. This functionality makes it an ideal treatment of solid tumours due to its strong potency, enhanced tumour access and long tissue half-life.
Epsilogen’s lead product candidate, MOv18 IgE, is the first therapeutic IgE antibody to enter the clinic and encouraging data from a completed Phase I trial demonstrated MOv18 IgE to be safe and well tolerated with early signs of clinical activity. Epsilogen has recently successfully completed large scale GMP manufacture of MOv18 IgE (the first time this has been achieved for an IgE antibody) and will initiate a Phase Ib trial in Platinum Resistant Ovarian Cancer Patients later this year. The company is also developing a proprietary IgEG antibody platform combining elements from both IgE and IgG antibodies into novel and proprietary antibody molecules with enhanced functionality.
Epsilogen began operations in 2017 as a spin-out of King’s College London and has attracted venture capital financing from Epidarex Capital, Novartis Venture Fund, 3B Future Health, British Patient Capital, ALSA Ventures and Schroders Capital amongst others. Find out more at epsilogen.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240430482968/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom